Inflammatory Bowel Disease (IBD) involving the colon is a known risk for colon cancer.
There are two standards-of-care colonoscopy techniques used for screening all patients
who suffer from IBD for more than eight years. One method is to obtain random biopsies
throughout the colon and the other is by using dye spraying chromo-colonoscopy.
This trial aims to study the difference between the two colonoscopy techniques during the
era of high definition camera in detecting neoplastic lesions during screening patients
with long-standing IBD.
Additional locations may be listed on ClinicalTrials.gov for NCT04191655.
See trial information on ClinicalTrials.gov for a list of participating sites.
Research Question:
Is High Definition White Light Colonoscopy (HDWLC) not inferior to Dye Spraying
Chromo-colonoscopy (DSC) in detecting all neoplastic lesions during screening patients
with colonic IBD for more than eight years?
Study setting: The study will be conducted at Beth Israel Deaconess Medical Center.
Patients will be randomized to HDWLC with biopsies every 10 cm versus DSC.
Study population: Adult patients colonic IBD for more than eight years.
Recruitment The study team will conduct a day by day chart review for all patients with a
history of inflammatory bowel disease who were scheduled for screening colonoscopy and
find candidates who meet the eligibility criteria. A study team member will meet with the
potential candidates during their visit to the gastroenterology procedure room before
having their colonoscopy and offer them to participate in the study.
Procedures: Participants will undergo either HDWLC with biopsies every 10 cm or DSC based
on the randomization. Both procedures are standard of care and are being done at BIDMC
before starting this study. All the endoscopists are IBD specialists with expertise in
both procedures. All physicians were given a review article and video of chromoendoscopy
to further standardize practice. The clinicians who are conducting the HDWLC are allowed
to do a targeted DSC if required as per hospital protocol. Both arms of the study are
using high definition Olympus colonoscopes
Study design: A randomized controlled, noninferiority trial.
Sample size:
Existing literatures suggest that the detection rate of the DSC arm is 20%. The
investigators set 10% as the non-inferiority margin. With a total of 400 subjects (200 in
each arm), the study will have 80% power to detect non-inferiority with the type I error
rate controlled at 0.05. To account for a potential 25% data attribution, the study team
will enroll 500 subjects.
Statistical Analysis:
The baseline characteristics of the two trial arms will first be tabulated for potential
imbalance in variables. Continuous variables will be summarized by typical parameters
such as mean, standard deviation and range and compared using two-sample T-test (if the
normality assumption holds) or Wilcoxon rank-sum test (if the normality assumption does
not hold). Normality of distribution will be determined using the Kolmogorov-Smirnov
goodness-of-fit test. Categorical data will be summarized by frequency and percentage and
analyzed using the Chi-square or Fishers exact test, as appropriate.
The primary outcome will be compared using Z-test based on normal approximation of the
sample proportions.
Outcome analysis:
Primary outcome analysis: Intention to treat Secondary outcome analysis: Per protocol
analysis.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationBeth Israel Deaconess Medical Center